Chong Kun Dang Pharmaceutical (185750) - Cash Flow Conversion Efficiency

Latest as of March 2026: 0.012x

Based on the latest financial reports, Chong Kun Dang Pharmaceutical (185750) has a cash flow conversion efficiency ratio of 0.012x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩12.32 Billion ≈ $8.35 Million USD) by net assets (₩1.03 Trillion ≈ $697.19 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See debt-free asset ratio of Chong Kun Dang Pharmaceutical to measure how much of total assets are equity-financed.

Chong Kun Dang Pharmaceutical - Cash Flow Conversion Efficiency Trend (2016–2025)

This chart illustrates how Chong Kun Dang Pharmaceutical's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Chong Kun Dang Pharmaceutical cash earnings quality to evaluate the quality of earnings relative to operating cash generation.

Chong Kun Dang Pharmaceutical Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Chong Kun Dang Pharmaceutical ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Ji'an Mankun Technology Co. Ltd. A SHE:301132	0.015x
Jiangsu Liba Enterprise Joint-Stock Co Ltd SHG:603519	0.051x
Royce Micro Cap Closed Fund NYSE:RMT	-0.003x
Ray Sigorta AS IS:RAYSG	-0.027x
SK Discovery Co Ltd KO:006120	0.036x
EPC Groupe PA:EXPL	0.235x
Shenzhen Guangju Energy Co Ltd SHE:000096	0.003x
Bestlink Tech Co Ltd SHG:603206	-0.067x

Annual Cash Flow Conversion Efficiency for Chong Kun Dang Pharmaceutical (2016–2025)

The table below shows the annual cash flow conversion efficiency of Chong Kun Dang Pharmaceutical from 2016 to 2025. For the full company profile with market capitalisation and key ratios, see Chong Kun Dang Pharmaceutical market cap and net worth.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	₩1.01 Trillion ≈ $681.99 Million	₩67.36 Billion ≈ $45.65 Million	0.067x	-6.68%
2024-12-31	₩896.38 Billion ≈ $607.46 Million	₩64.29 Billion ≈ $43.57 Million	0.072x	-81.61%
2023-12-31	₩815.64 Billion ≈ $552.74 Million	₩318.16 Billion ≈ $215.61 Million	0.390x	+257.79%
2022-12-31	₩621.29 Billion ≈ $421.04 Million	₩67.73 Billion ≈ $45.90 Million	0.109x	+378.04%
2021-12-31	₩565.81 Billion ≈ $383.44 Million	₩12.90 Billion ≈ $8.74 Million	0.023x	-87.94%
2020-12-31	₩551.59 Billion ≈ $373.81 Million	₩104.32 Billion ≈ $70.70 Million	0.189x	+16.22%
2019-12-31	₩474.95 Billion ≈ $321.87 Million	₩77.29 Billion ≈ $52.38 Million	0.163x	+64.50%
2018-12-31	₩430.90 Billion ≈ $292.01 Million	₩42.63 Billion ≈ $28.89 Million	0.099x	-51.15%
2017-12-31	₩403.29 Billion ≈ $273.31 Million	₩81.67 Billion ≈ $55.35 Million	0.203x	+24.15%
2016-12-31	₩354.25 Billion ≈ $240.07 Million	₩57.79 Billion ≈ $39.16 Million	0.163x	--

About Chong Kun Dang Pharmaceutical

KO:185750 Korea Drug Manufacturers - Specialty & Generic

Market Cap

$597.37 Million

₩881.48 Billion KRW

Market Cap Rank

#11150 Global

#286 in Korea

Share Price

₩66900.00

Change (1 day)

-0.45%

52-Week Range

₩64100.00 - ₩97700.00

All Time High

₩207617.05